XLRN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases...

Stats
Šios dienos apimtis	7.88M
Vidutinė apimtis	1.27M
Rinkos kapitalizacija	0.00
EPS	$-1.160 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$2.64 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-19	Zakrzewski Joseph S	Sell	34 499	Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	10 000	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	7 500	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	7 500	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	10 000	Option to Purchase Common Stock

INSIDER POWER
0.00
Last 100 transactions
Buy: 155 406 \| Sell: 743 673

Tūris Koreliacija

Ilgas: 0.40 (neutral)

Trumpas: 0.62 (weak)

Signal:(71.182) Neutral

Acceleron Pharma Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APAC	0.971
THCPU	0.97
WTMA	0.97
ALGN	0.966
CRUS	0.963
ALGM	0.961
ATRS	0.961
IQ	0.96
NVAC	0.96
BLDR	0.959

10 Labiausiai neigiamai susiję koreliacijos
NAKD	-0.958
PROC	-0.953
MTEX	-0.949
AHPI	-0.949
GRIN	-0.946
TRIT	-0.94
PIII	-0.938
LCAP	-0.935
CYTO	-0.935
LAWS	-0.934

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Acceleron Pharma Inc Koreliacija - Valiuta/Žaliavos

-0.13
( neutral )

0.62
( weak )

0.56
( weak )

0.08
( neutral )

0.22
( neutral )

0.17
( neutral )

Acceleron Pharma Inc Finansinės ataskaitos

Annual	2020
Pajamos:	$92.52M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.92

FY	2020
Pajamos:	$92.52M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.92

FY	2019
Pajamos:	$73.99M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.38

FY	2018
Pajamos:	$13.99M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.59

Financial Reports:

No articles found.

Acceleron Pharma Inc

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.